High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - The tamip study
Background: Primary percutaneous coronary intervention (PCI) has been shown to be an effective therapy for patients with acute myocardial infarction (MI). Glycoprotein (GP) IIb/IIIa receptor blockers reduce thrombotic complications in patients undergoing PCI. Most available data relate to Reopro, wh...
Main Author: | Mohammed A Balghith |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Heart Views |
Subjects: | |
Online Access: | http://www.heartviews.org/article.asp?issn=1995-705X;year=2012;volume=13;issue=3;spage=85;epage=90;aulast=Balghith |
Similar Items
-
Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban
by: T. A. Batyraliev, et al.
Published: (2008-12-01) -
Alveolar Hemorrhage during Abciximab Infusion
by: Yavuzer Koza, et al.
Published: (2021-01-01) -
Effect of intracoronary sodium nitroprusside and tirofiban injection on myocardial injury in patients with no reflow in PCI
by: Xiang-Yang Xia
Published: (2018-04-01) -
Effect of tirofiban combined with PCI on myocardial damage and platelet activation in patients with STEMI
by: Guo-Hua Shi
Published: (2018-01-01) -
Effect of papaverine combined with tirofiban intracoronary injection on the degree of myocardial injury in patients with no reflow during PCI
by: De-Yin Zeng, et al.
Published: (2018-09-01)